Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Tumours with PI3K activation are resistant to dietary restriction.

Kalaany NY, Sabatini DM.

Nature. 2009 Apr 9;458(7239):725-31. doi: 10.1038/nature07782. Epub 2009 Mar 11.

2.

Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction.

Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, Jacks T, Sabatini DM, Kalaany NY.

Cancer Discov. 2013 Aug;3(8):908-21. doi: 10.1158/2159-8290.CD-12-0507. Epub 2013 May 29.

3.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.

4.

Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism.

Palian BM, Rohira AD, Johnson SA, He L, Zheng N, Dubeau L, Stiles BL, Johnson DL.

PLoS Genet. 2014 Dec 11;10(12):e1004789. doi: 10.1371/journal.pgen.1004789. eCollection 2014 Dec. Erratum in: PLoS Genet. 2015 Mar;11(3):e1005055.

5.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

6.

Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.

Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC.

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10238-43. Epub 2005 Jul 8.

7.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
8.

Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.

Bertram J, Peacock JW, Tan C, Mui AL, Chung SW, Gleave ME, Dedhar S, Cox ME, Ong CJ.

Cancer Res. 2006 May 1;66(9):4781-8.

9.

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.

Cully M, You H, Levine AJ, Mak TW.

Nat Rev Cancer. 2006 Mar;6(3):184-92. Review.

PMID:
16453012
10.

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G.

Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.

11.

The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, Thiagarajan P, Mancini MA, Marcelli M.

Prostate. 2013 Feb 15;73(3):267-77. doi: 10.1002/pros.22566. Epub 2012 Jul 20.

12.

PTEN-deficient cancers depend on PIK3CB.

Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28.

13.

Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.

Xie C, Lu H, Nomura A, Hanse EA, Forster CL, Parker JB, Linden MA, Karasch C, Hallstrom TC.

Mol Cancer. 2015 Apr 24;14:93. doi: 10.1186/s12943-015-0360-y.

14.

Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.

Yan X, Fraser M, Qiu Q, Tsang BK.

Gynecol Oncol. 2006 Aug;102(2):348-55. Epub 2006 Mar 20.

PMID:
16545436
15.

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H.

Cancer Res. 2009 Nov 1;69(21):8386-94. doi: 10.1158/0008-5472.CAN-09-1504. Epub 2009 Oct 13.

16.

PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.

Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS, Li W.

Oncogene. 2002 Aug 8;21(34):5289-300.

17.

Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo.

Saito Y, Swanson X, Mhashilkar AM, Oida Y, Schrock R, Branch CD, Chada S, Zumstein L, Ramesh R.

Gene Ther. 2003 Nov;10(23):1961-9.

PMID:
14528320
18.

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.

Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A.

Cancer Biol Ther. 2008 Feb;7(2):307-15. Epub 2007 Nov 21.

PMID:
18059185
19.

Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.

Kim S, Huang W, Mottillo EP, Sohail A, Ham YA, Conley-Lacomb MK, Kim CJ, Tzivion G, Kim HR, Wang S, Chen YQ, Fridman R.

Biochim Biophys Acta. 2010 Nov;1803(11):1287-97. doi: 10.1016/j.bbamcr.2010.06.011. Epub 2010 Jul 8.

20.

Supplemental Content

Support Center